ReviewMedComm2025
Tissue Engineering and Regenerative Medicine: Perspectives and Challenges.
Review in MedComm, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Exosome-based therapy for epilepsy: a systematic review and meta-analysis of preclinical studies.Frontiers in neuroscience · 2026Pooled it
- Optimizing dose and delivery route in mesenchymal stromal cells (MSCs)-based therapy: A systematic review of their implications for clinical efficacy.Cell transplantationPooled it
- Neurons Die Not by One Hit, but by Signaling Convergence.Molecular neurobiology · 2026Review
- Copper-Doped Silicate Porous Architectures for Hard Tissue Engineering.Journal of functional biomaterials · 2026Article
- Review
- Multiscale Modeling and Analysis of Muscle Tissue: A Finite Element Approach for 3D Braided Composite Structures.Biomimetics (Basel, Switzerland) · 2026Article
- From bone replacement to regeneration. A biomaterials started journey.Materials today. Bio · 2026Review
- Single-cell and spatial transcriptomics reveal Thbs1-CD36 crosstalk between Kupffer and hepatic stellate cells following mesenchymal stem cell-derived small extracellular vesicles transplantation, alleviating liver fibrosis.Journal of nanobiotechnology · 2026Article
- Regenerative Therapy at the Crossroads: From Cell-Based to Cell-Free Precision Medicine.Bioengineering (Basel, Switzerland) · 2026Article
- Analysis and prediction of cardiovascular research hotspots, trends and interdisciplinarity.Heart (British Cardiac Society) · 2026Article
- [Application and challenges of tissue engineered scaffolds in treatment of long-segment laryngotracheal stenosis].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2026Review
- The immunomodulatory power of mesenchymal stem/stromal cell-derived extracellular vesicles in bone disorders: A comprehensive review.Clinical and experimental medicine · 2026Review
- Self-driving bioprinting laboratories.Biofabrication · 2026Review
- Polylactide/Polycaprolactone Nanofiber Scaffold Enhances Primary Cortical Neuron Growth.Polymers · 2026Article
- Article
- Knowledge and attitude of Malaysian university students towards regenerative medicine therapy and their clinical implications: a cross-sectional study.Frontiers in genetics · 2026Article
- Three-dimensional bioprinted organoids: advances and clinical translation.Regenerative biomaterials · 2026Review
- Regenerative strategies for surfactant deficiency in neonatal and pediatric lung disease: the role of mesenchymal stem cells and their extracellular vesicles.Frontiers in cell and developmental biology · 2026Review
- Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration.International journal of molecular sciences · 2025Article
- Current Mechanobiological Pathways and Therapies Driving Spinal Health.Bioengineering (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
From the pioneering days of cell therapy to the achievement of bioprinting organs, tissue engineering, and regenerative medicine have seen tremendous technological advancements, offering solutions for restoring damaged tissues and organs. However, only a few products and technologies have received United States Food and Drug Administration approval. This review highlights significant progress in cell therapy, extracellular vesicle-based therapy, and tissue engineering. Hematopoietic stem cell transplantation is a powerful tool for treating many diseases, especially hematological malignancies. Mesenchymal stem cells have been extensively studied. The discovery of induced pluripotent stem cells has revolutionized disease modeling and regenerative applications, paving the way for personalized medicine. Gene therapy represents an innovative approach to the treatment of genetic disorders. Additionally, extracellular vesicle-based therapies have emerged as rising stars, offering promising solutions in diagnostics, cell-free therapeutics, drug delivery, and targeted therapy. Advances in tissue engineering enable complex tissue constructs, further transforming the field. Despite these advancements, many technical, ethical, and regulatory challenges remain. This review addresses the current bottlenecks, emphasizing novel technologies and interdisciplinary research to overcome these hurdles. Standardizing practices and conducting clinical trials will balance innovation and regulation, improving patient outcomes and quality of life.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.